Article: Treatment

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial

J. Satoh*, S. Yagihashi†, M. Baba‡, M. Suzuki§, A. Arakawa§, T. Yoshiyama§ and S. Shoji§

*Division of Diabetes and Metabolism, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan, †Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ‡Department of Neurology, Aomori Prefectural Central Hospital, Aomori, Japan and §Clinical Research and Clinical Statistics, Pfizer Japan Inc., Tokyo, Japan

Abstract

Aims   To evaluate the efficacy, safety and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients.

Methods   A randomized, double-blind, placebo-controlled, multicentre 14 week clinical trial was conducted. Japanese patients with diabetic peripheral neuropathy ($n = 317$) were randomized to receive placebo or pregabalin at 300 or 600 mg/day. The primary efficacy measure was a change of mean pain score from baseline to end-point from patients' daily pain diaries.

Results   Significant reductions in pain were observed in patients treated with pregabalin at 300 and 600 mg/day vs. placebo ($P < 0.05$). Improvements in weekly pain scores were observed as early as week 1 and were sustained throughout the study period (300 and 600 mg/day difference from placebo at study end-point, –0.63 and –0.74, respectively). Pregabalin produced significant improvements in weekly sleep interference scores, the short-form McGill Pain Questionnaire, the Medical Outcomes Study–Sleep Scale, the 36-item Short-Form Health Survey scale, and the Patient and Clinical Global Impression of Change. Patient impressions of numbness, pain and paraesthesia were also significantly improved. Regarding treatment responders, 29.1 and 35.6% of patients treated with 300 and 600 mg/day, respectively, reported ≥50% improvement in mean pain scores (vs. 21.5% for placebo). Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate.

Conclusions   Pregabalin was effective in reducing pain and improving sleep disturbances due to pain, and was well tolerated in Japanese patients with painful DPN.

Diabet. Med. 28, 109–116 (2011)

Keywords   clinical trial, diabetes mellitus, peripheral neuropathic pain, pregabalin, sleep

Abbreviations   CGIC, Clinical Global Impression of Change; CL_{cr}, creatinine clearance; MOS, Medical Outcomes Study; PGIC, Patient Global Impression of Change; SF-36, 36-item Short-Form Health Survey; SF-MPQ, Short-Form McGill Pain Questionnaire.

Introduction

The number of patients with diabetes mellitus increases yearly in Japan. The estimated prevalence was 6.8 million in 2000 and is expected to grow to 8.9 million in 2030, which places Japan among the top 10 countries for prevalence of patients with diabetes [1]. Consequently, an increase in patients with vascular and neurological complications is expected.

Diabetic peripheral neuropathy is one of the most common complications associated with diabetes and consists of several distinct clinical entities categorized as sensory, focal and multifocal or autonomic [2,3]. Painful neuropathic symptoms are associated not only with discomfort but also with sleep interference, weight loss, anxiety, depression and an overall decrease in quality of life [4–9], the impact of which increases with pain severity [4]. In addition, a large proportion of patients

Correspondence to: Jo Satoh, Division of Diabetes and Metabolism, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. E-mail: jsatoh@iwate-med.ac.jp

109

with diabetic peripheral neuropathy report limited activity and lost productivity at work [4].

There is a need for pharmacological treatment options that can relieve the painful symptoms of diabetic peripheral neuropathy. Drugs such as antidepressants, antiepileptics, topical treatments and opioids have been used to date [10,11]. In addition to these, epalrestat (aldose reductase inhibitor) and mexiletine (anti-arrhythmic) have been approved to treat symptoms of this condition in Japan. Despite these advances, the pharmacological treatment of painful diabetic peripheral neuropathy continues to be a challenge for the physician.

Pregabalin binds with high affinity to the $\alpha_2\delta$ site and has analgesic, anxiolytic and anticonvulsant activities. Pregabalin has become one of the first-line treatments for painful diabetic peripheral neuropathy in many Western countries, as several Phase 3 clinical studies have confirmed its efficacy and safety [12–17].

The present study was undertaken to evaluate the efficacy, safety and pharmacokinetics of pregabalin for painful diabetic peripheral neuropathy in Japanese patients. As the efficacy and safety profile of pregabalin was considered similar between Japanese and Western patients with postherpetic neuralgia [18,19], this study included doses similar to those in previous studies of diabetic peripheral neuropathy conducted in the West.

Patients and methods

Study population

Patients included men and women ≥18 years of age diagnosed with Type 1 or Type 2 diabetes mellitus at least 1 year previously and diagnosed with painful distal, symmetrical, sensorimotor polyneuropathy due to diabetes. Patients were enrolled if they had a score of ≥40 mm on the visual analogue scale of the short-form McGill Pain Questionnaire (SF-MPQ) and had evaluated and recorded pain for at least 4 of the previous 7 days in the daily pain diary prior to treatment initiation, with the mean score being ≥4 on an 11-point (0–10) numeric rating scale. Patients excluded were those diagnosed with a malignant tumour within the past 2 years, those whose creatinine clearance (CL_{cr}), calculated according to the Cockcroft & Gault formula [20], was ≤0.5 ml/s (≤30 ml/min), and those who had pain or skin conditions that may affect the evaluation of pain.

Study design

The study consisted of a 1 week baseline phase, a 13 week treatment phase and a 1 week down-titration phase. Patients were classified into two groups based on CL_{cr} (0.5 < CL_{cr} ≤ 1.0 ml/s or CL_{cr} > 1.0 ml/s) and then randomized to one of three treatment groups (placebo, pregabalin 300 or pregabalin 600 mg/day). Patients randomized to 600 mg/day with 0.5 < CL_{cr} ≤1.0 ml/s received 300 mg/day. The stratified randomization based on CL_{cr} stratum was centrally organized using a validated web-based system.

During the 1 week titration phase, the initial dose was 75 mg twice daily and was slowly increased until the target dose was reached. Patients then took pregabalin 150 or 300 mg or placebo twice daily during the 12 week fixed-dose treatment phase. Patients who did not enter the long-term open-label extension concluded dosing following a 1 week dosage taper phase. The study was approved by the institutional review boards and conducted in compliance with the Declaration of Helsinki, International Conference on Harmonization Good Clinical Practices guidelines and Japanese regulations at 62 sites from October 2007 to March 2009 (first subject, first visit to last subject, last visit), and registered under the Clinical Trials Registry number NCT00553475. All patients provided written informed consent.

Efficacy and safety assessments

The primary efficacy end-point was the change from baseline in mean weekly pain score from the patient's daily pain diary at week 13 [study end-point (last observation carried forward)] using an 11-point numeric rating scale.

Secondary efficacy end-points included weekly mean pain scores, responder rates (defined as ≥50% reduction in mean pain score from baseline to end-point), SF-MPQ completed at each clinic visit, and weekly mean sleep interference scores using an 11-point numeric rating scale. Additional efficacy measures included Medical Outcomes Study (MOS)–Sleep Scale, 36-item Short-Form Health Survey (SF-36) [21], patient impression of subjective symptoms (numbness, pain and paraesthesia), Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).

Adverse events were recorded from the first dosing of the study drug to the last visit of the study. Physical examinations and laboratory assessments were conducted at multiple times throughout the study. Plasma concentrations of pregabalin were assessed by blood samples at weeks 8 and 13 of the treatment phase.

Population pharmacokinetic analysis

Blood samples were collected from 154 patients (*n* = 298). Plasma pregabalin concentration samples were assayed using a validated liquid chromatography/tandem mass spectrometry. The lower limit of quantification was 0.157 μmol/l. The analysis was performed using non-linear mixed effects modelling methodology as implemented in NONMEM (version 5; ICON Development Solutions, Ellicott City, MD, USA). A one-compartment model with first-order absorption and elimination (NONMEM subroutine ADVAN2) was fitted to pregabalin concentrations.

Statistical analyses

A sample size of 308 patients (*n* = 132 for both placebo and 300 mg/day groups, and *n* = 44 for 600 mg/day group) was

targeted. Differences against placebo in the change from baseline in mean weekly pain score were estimated at −1.0 for 300 mg/day and −1.6 for 600 mg/day with common standard deviation of 2.4 based on the results of Western studies [14,16,17]. To detect the difference between placebo and 300 mg/day with at least 90% power, 130 patients for each group were required. In addition, to show the superiority of 600 mg/day to placebo with almost 90% probability together with detection of the difference between placebo and 300 mg/day groups, 3:3:1 randomization ratio was selected.

All patients who received at least one dose of study drug with baseline and at least one postbaseline efficacy measurement were included in the efficacy analyses. The primary comparison was pregabalin 300 mg/day vs. placebo with respect to change from baseline in mean weekly pain score. An analysis of covariance (ANCOVA) model with treatment and CL_{cr} stratum as factors and baseline mean weekly pain score as a covariate was used for the comparison. The key secondary analysis was to compare 600 mg/day with placebo. Significance level for testing the treatment effect was 0.05. No adjustments were made for multiplicity, since all comparisons, except for a single primary comparison, were considered secondary and were used to support the findings of the primary analysis. The same ANCOVA model as the primary analysis was used for secondary analyses of continuous data. The Cochran–Mantel–Haenszel chi-square test was used for secondary analyses of categorical data.

All patients who received at least one dose of study drug were included in the safety analyses. Safety end-points were summarized descriptively by treatment group, and no inferential analyses were conducted.

Results

Patient disposition/demographics

In total, 317 patients were randomized to groups of placebo (*n* = 136), 300 mg/day (*n* = 136) or 600 mg/day (*n* = 45). The analysis set for efficacy and safety included 314 patients. Three of the randomized patients discontinued the study before taking study drug owing to protocol violations. Patients were well matched on demographic and baseline characteristics (Table 1) [22]. Eighty-four per cent of patients (placebo, *n* = 119; 300 mg/day, *n* = 114; 600 mg/day, *n* = 32) who were treated completed the study, while 16 patients (11.8%) in the placebo group, 20 patients (14.7%) in the 300 mg/day group and 13 patients (28.9%) in the 600 mg/day group withdrew from the study. The most common reason for discontinuation was treatment-related adverse events, which occurred in six patients (4.4%) in the placebo group, 10 patients (7.5%) in the 300 mg/day group and 12 patients (26.7%) in the 600 mg/day group. In the placebo group, seven patients (5.2%) discontinued owing to lack of symptom improvements.

Table 1 Demographic characteristics

	Placebo (*n* = 135)	Pregabalin 300 mg/day (*n* = 134)	Pregabalin 600 mg/day (*n* = 45)
Women, *n* (%)	32 (23.7)	32 (23.9)	13 (28.9)
Age (years)			
Mean (SD)	61.3 (9.6)	61.3 (10.3)	62.2 (10.3)
Range	35–85	35–85	41–78
Weight (kg)			
Mean (SD)	64.9 (12.8)	65.9 (12.7)	65.3 (13.1)
Range	41–104	31–113	37–105
Estimated CLcr at screening (mL/s)			
Mean (SD)	1.62 (0.62)	1.65 (0.58)	1.55 (0.46)
Diabetes type, n (%)			
Type 1	5 (3.7)	6 (4.5)	1 (2.2)
Type 2	130 (96.3)	128 (95.5)	44 (97.8)
HbA$_{1c}$ values (%) (JDS)*			
Mean (SD)	7.2 (1.1)	6.9 (1.1)	7.2 (1.1)
Range	4.9–10.2	4.6–10.1	4.7–9.6
HbA$_{1c}$ values (%) (NGSP)†			
Mean (SD)	7.6 (1.1)	7.3 (1.1)	7.6 (1.1)
Range	5.3–10.6	5.0–10.5	5.1–10.0
HbA$_{1c}$ values (mmol/mol)‡			
Mean (SD)	59 (12)	57 (12)	60 (12)
Range	34–92	31–91	32–86
Duration of Type 1 diabetes (years)			
Mean (SD)	12.5 (8.9)	13.8 (9.1)	15.7
Median	9.9	12.7	15.7
Range	3.3–23.9	4.5–26.9	—
Duration of Type 2 diabetes (years)			
Mean (SD)	14.0 (9.1)	13.3 (10.1)	14.5 (9.6)
Median	13.1	11.1	12.5
Range	1.2–40.6	1.1–56.6	1.0–40.0
Duration of peripheral neuropathic pain (years)			
Mean (SD)	4.2 (3.1)	4.3 (3.6)	4.5 (3.9)
Median	3.4	3.1	2.9
Range	1.0–19.5	1.1–20.8	1.1–15.4
Baseline mean pain score			
Mean (SD)	6.1 (1.4)	6.0 (1.4)	6.1 (1.3)
Median	6.0	5.9	6.1
Range	4.0–9.4	4.0–9.9	4.0–9.3

CL_{cr}, creatinine clearance; HbA$_{1c}$, glycated haemoglobin; JDS, Japan Diabetes Society; NGSP, National Glycohemoglobin Standardization Program.

* HbA$_{1c}$ values (%) measured using the standard substance by JDS, and these are 0.4% lower than those by NGSP.

† The value for HbA$_{1c}$ (%) is estimated as an NGSP equivalent value (%) calculated by the formula HbA$_{1c}$ (%) = HbA$_{1c}$ (JDS) (%) + 0.4%, considering the relational expression of HbA$_{1c}$ (JDS) (%) measured by the previous Japanese standard substance and measurement methods for HbA$_{1c}$ (NGSP) [22].

‡ HbA$_{1c}$ values (NGSP equivalent value) are converted to the HbA$_{1c}$ values (mmol/mol) (International Federation of Clinical Chemistry and Laboratory Medicine, IFCC).

Primary efficacy measure

Treatment with pregabalin at 300 and 600 mg/day resulted in statistically significant reductions in mean pain scores from baseline to study end-point compared with placebo (Fig. 1a). The difference from placebo was −0.63 [95% confidence interval

FIGURE 1 (a) Least-squares (LS) mean pain score change from baseline to end-point. Values below bars indicate sample sizes. (b) Change from baseline in weekly mean pain and sleep interference scores. (c) Percentage of patients rating themselves as 'improved' on symptoms of numbness, pain and paraesthesia. (d) Predicted plasma pregabalin concentration (hatched region) vs. time profile at steady state and observed plasma pregabalin concentrations (circles and triangles) by dose and creatinine clearance (CL_{cr}). The upper limit of the region indicates 97.5 percentile points of simulated 500 individuals with CL_{cr} = 1.0 ml/s (150 mg twice daily in the top panel and 300 mg twice daily in the bottom panel), and the lower limit indicates the 2.5 percentile points of those with CL_{cr} = 1.82 ml/s (150 mg twice daily in the top panel and 300 mg twice daily in the bottom panel). *P < 0.05, †P < 0.01. $AUC_{0-12,ss}$, steady-state area under the concentration–time curve from 0 to 12 h. BID, twice daily CL/F, oral clearance.

(CI), −1.09 to −0.17; P = 0.0075] and −0.74 (95% CI, −1.39 to −0.09; P = 0.0254) for the 300 and 600 mg/day pregabalin groups, respectively.

Secondary efficacy measures

Weekly pain scores for both pregabalin groups were significantly superior to the placebo group from weeks 1 through 13 (Fig. 1b). Overall, from baseline to end-point, the proportion of responders was higher in the 300 (29.1%) and 600 mg/day groups (35.6%)

relative to the placebo group (21.5%), but no significant differences were found.

The mean sleep interference scores at the study end-point were significantly improved in the 300 and 600 mg/day groups compared with placebo (P < 0.0001 for 300 mg/day and P = 0.0273 for 600 mg/day vs. placebo). The improved sleep interference scores were significant at week 1 and continued throughout the study (Fig. 1b).

The mean values of the sensory, affective, total, visual analogue scale and Present Pain Intensity scores of the SF-MPQ

in the 300 and 600 mg/day groups were significantly superior to those observed in the placebo group ($P < 0.05$), with the exception of the affective score at 600 mg/day ($P = 0.0707$). On the MOS–Sleep Scale, the 300 mg/day group showed significant improvement on several subscales, including sleep disturbance ($P = 0.0019$), quantity of sleep ($P = 0.0177$) and overall Sleep Problems Index ($P = 0.0269$) compared with the placebo group; the 600 mg/day group was significantly superior to placebo on sleep adequacy ($P = 0.0173$).

Patient impressions of subjective symptoms (numbness, pain and paraesthesia) were favourable for pregabalin (Fig. 1c). Patients treated with 300 mg/day reported significant improvements in numbness ($P = 0.0072$) and pain ($P = 0.0019$), while patients treated with 600 mg/day reported a significant improvement in paraesthesia ($P = 0.0093$). There was a significant difference in the PGIC scores favouring the 600 mg/day group compared with placebo ($P = 0.0075$), and in the CGIC scores favouring both pregabalin groups compared with placebo (300 mg/day, $P = 0.0148$; 600 mg/day, $P = 0.0063$). Evaluation of health survey scores using the SF-36 revealed that pregabalin 600 mg/day was significantly superior to the placebo group on social functioning and vitality ($P < 0.05$).

Safety

A summary of the most common treatment-related adverse events and their discontinuation rates is provided in Table 2. The incidence of patients with one or more treatment-related adverse events in placebo, 300 and 600 mg/day groups was 36, 57 and 80%, respectively. Somnolence (26%), dizziness (24%), peripheral oedema (13%) and increased weight (11%) occurred most frequently in patients treated with pregabalin and appeared to be dose related. In all treatment groups, most of the adverse events were reported as mild or moderate.

Severe treatment-related adverse events were observed in two patients [one patient (diabetic nephropathy, 300 mg/day group) and one patient (somnolence, 600 mg/day group)], but were confirmed to have resolved after discontinuation of the study treatment.

Serious adverse events were observed in nine patients (three patients in the placebo group, four patients in the 300 mg/day group and two patients in the 600 mg/day group). All the serious adverse events observed in the pregabalin groups (six patients) were judged to have no causal relationship with the study drug. No severe or serious adverse events related to laboratory values, vital signs, electrocardiograms and neurological and ophthalmological examinations were observed in the pregabalin groups. Mean change in body weight from baseline to the final assessment was greater in the 300 and 600 mg/day groups compared with the placebo group (0.09, 1.59 and 1.72 kg, respectively). Blood glucose levels and glycated haemoglobin concentrations remained unchanged from baseline to the final assessment in patients treated with either placebo or pregabalin.

The proportion of discontinued patients owing to adverse events (all causes) was highest in the 600 mg/day group (28.9%, 13 patients), followed by the 300 mg/day group (12.7%, 17 patients) and the placebo group (5.2%, seven patients). The adverse events considered to be mostly responsible for discontinuation were dizziness (two patients in the placebo group, three patients in the 300 mg/day group and five patients in the 600 mg/day group] and somnolence (two patients in the 600 mg/day group).

Population pharmacokinetics

The steady-state predicted and observed plasma pregabalin concentrations by dose and CL_{cr} are shown in Fig. 1d. Most of the observed pregabalin concentrations in patients with $CL_{cr} > 1.0$ ml/s were within each predicted range. In patients with $0.5 < CL_{cr} \leq 1.0$ ml/s who received pregabalin 150 mg twice daily (300 mg/day), most of the concentrations fell within the predicted range of 300 mg twice daily (600 mg/day). Steady-state area under the concentration–time curve from 0 to 12 h

Table 2 Treatment-related adverse events and discontinuations occurring in $\geq 3\%$ of any treatment group

	Placebo ($n = 135$)		Pregabalin 300 mg/day ($n = 134$)		Pregabalin 600 mg/day ($n = 45$)	
	n (%)	Discontinuation n (%)	n (%)	Discontinuation n (%)	n (%)	Discontinuation n (%)
Somnolence	11 (8.1)	0	28 (20.9)	0	18 (40.0)	2 (4.4)
Dizziness	9 (6.7)	2 (1.5)	26 (19.4)	3 (2.2)	17 (37.8)	5 (11.1)
Peripheral oedema	6 (4.4)	0	17 (12.7)	0	6 (13.3)	0
Weight increased	3 (2.2)	0	15 (11.2)	1 (0.7)	5 (11.1)	0
Constipation	1 (0.7)	0	4 (3.0)	0	2 (4.4)	0
Oedema	1 (0.7)	0	3 (2.2)	0	2 (4.4)	1 (2.2)
Face oedema	0	0	5 (3.7)	0	1 (2.2)	0
Blood creatine phosphokinase increased	0	0	2 (1.5)	0	2 (4.4)	0
Hot flush	1 (0.7)	0	1 (0.7)	0	2 (4.4)	0
Muscular weakness	0	0	0	0	2 (4.4)	0

during multiple oral dose treatment with pregabalin 150 mg twice daily (300 mg/day) in patients with impaired kidney function ($0.5 < CL_{cr} \leq 1.0$ ml/s) was the same as that observed during multiple oral dose treatment with pregabalin 300 mg twice daily (600 mg/day) in patients with $CL_{cr} > 1.0$ ml/s (504 vs. 474 µmol h/l). In addition, the clearance of pregabalin in patients with impaired kidney function was about half of the clearance in patients with $CL_{cr} > 1.0$ ml/s (0.54 vs. 1.15 ml/s).

Discussion

The results from this trial demonstrate that pregabalin is efficacious in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients. Both the 300 and 600 mg/day groups showed statistical improvement over placebo in reducing mean pain scores. This effect was observed as early as the first week and was maintained throughout the study. The proportion of patients responding to treatment (≥50% improvement in mean pain score from baseline) was higher (albeit not significant) in the 300 (29.1%) and 600 mg/day (35.6%) pregabalin groups relative to the placebo group (21.5%). These responder rates are somewhat lower than those reported in previously published studies (39 and 47% for 300 and 600 mg/day, respectively [23]), despite comparable placebo responder rates (22%). The reason for the potentially lower treatment response is unknown, but with regard to the proportion of patients with ≥30% improvement in mean pain score from baseline (36, 49 and 56% for placebo, 300 and 600 mg/day, respectively), (another well-known efficacy measure considered to be clinically important [24]), there were no major differences from those reported previously in published studies (37, 55 and 62% for placebo, 300 and 600 mg/day, respectively [23]).

Secondary efficacy measures also supported the superiority of pregabalin over placebo. Scores from the SF-MPQ were significantly improved over placebo, as were the sleep interference scores. Among the MOS-Sleep subscales, sleep adequacy, sleep disturbances, sleep quantity and sleep problems showed improvement at either the 300 and the 600 mg/day doses. PGIC and CGIC also improved in pregabalin-treated patients.

This is the first study to report on patient impressions of symptom improvement in numbness and paraesthesia, which are cardinal symptoms of diabetic peripheral neuropathy. Significant improvements were observed at either doses, albeit on different symptoms. The reason for this differential effect is unclear, but the overall improvement illustrates the efficacy of pregabalin in treating a variety of neuropathic symptoms beyond pain. Finally, health evaluation using the SF-36 revealed that pregabalin 600 mg/day was superior to placebo in social functioning and vitality, a positive finding partly consistent with a previous study [14].

The frequency and severity of adverse events in pregabalin-treated patients were similar to those reported in previous studies [12–17]. The most common adverse events were somnolence, dizziness, peripheral oedema and weight gain, all of which appeared to be dose related and were reported generally as mild to moderate. The serious adverse events in patients treated with pregabalin were deemed unrelated to the study drug. Dizziness and somnolence were the most frequent adverse events leading to treatment discontinuation, but each represented less than 5% of the pregabalin-treated patients. In this study, pregabalin dosage adjustment was made based on calculated creatinine clearance. Population pharmacokinetic analysis confirmed that the magnitude of the dose adjustment was accurate.

Depression has been documented in a significant proportion of Japanese patients with diabetes and appears to be associated with the presence of DPN, among other factors [8]. Diabetic peripheral neuropathy also coincides with sleep disturbances, activity limitations and a decrease in quality of life [4–9]. In this study, pregabalin appeared to alleviate some of these disturbing sequelae. The impact of pregabalin on depression and activity limitations was not evaluated, but they remain important outcome variables for future study.

Mean pain score in the placebo group continued to decrease throughout the treatment period, and approximately 20% of the patients in the placebo group achieved a ≥50% reduction in their pain score from baseline to end-point. Although this proportion of patients is comparable to the placebo responder rate in other pregabalin trials in diabetic peripheral neuropathy[23], it is nevertheless substantial and reduces the likelihood of detecting a significant separation between the placebo and treatment groups. The placebo response in neuropathic pain trials is recognized as an important issue that merits the consideration of alternative trial designs [25,26].

Finally, this study did not include an active comparator. At present in Japan, the aldose reductase inhibitor, epalrestat, is approved to treat the underlying pathogenesis of diabetic peripheral neuropathy, but its predominant effect appears to be on improving nerve function [27,28]. Further study should compare the efficacy of pregabalin with epalrestat or other medications (e.g. mexiletine) and evaluate the combination of pregabalin with other therapeutic agents in the treatment of this painful condition.

Competing interests

114

List of principal investigators

Hideyuki Noro, Atsushi Hasegawa, Takeshi Terui, Shin Aoki, Kazurou Kaise, Shunya Sato, Kenichi Suzuki, Susumu Suzuki, Hiroshi Otani, Kenji Yaginuma, Yoshiya Katsura, Seiichi Nakayama, You Kageyama, Osamu Matsuda, Kuniaki Otsuka, Nobuyuki Sato, Toru Hiyoshi, Yasuhiko Iwamoto, Masao Ota, Shinichi Oikawa, Koujiro Ueki, Shu Meguro, Yukiko Onishi, Zenji Makita, Harumi Nishimura, Tetsuya Morishita, Keiichi Shimoda, Masahiko Takai, Tetsuro Takeda, Yukio Tanaka, Michio Nakagawa, Shunichi Kojima, Hideki Okamoto, Shigeichi Shouji, Sumiko Kato, Akiko Matsumoto, Kiyoshi Takekawa, Motoyoshi Ikebuchi, Kei Kotani, Kounosuke Marui, Ryo Nagase, Kouji Manabe, Hisayoshi Mochizuki, Tsuyoshi Torii, Hiroyuki Nodera, Kenta Sato, Sunao Matsubayashi, Keizo Anzai, Kenzo Iino, Kouichi Fukuda, Jun Watanabe, Atsushi Ogo, Akitaka Hisatomi, Toru Yoshimura, Kiyohiro Izumino, Hideaki Jinnouchi, Mikio Todaka, Kengo Kaneko, Taiji Sekigami, Youichi Tatsukawa, Masaharu Hiraga, Masazumi Takeshita, Yoshito Inobe, Osamu Kanashiro, Seitaro Nakama, Hideaki Tanaka, Nobuyuki Miyake, Hajime Ishii and Makoto Suda.

References

1 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004; 27: 1047–1053.

2 Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R *et al.* Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005; 28: 956–962.

3 Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. *Diabetes* 1997; 46(Suppl 2): S54–S57.

4 Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. *J Pain Symptom Manage* 2005; 30: 374–385.

5 Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H *et al.* Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. *Diabetes Metab* 2009; 35: 206–213.

6 Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS *et al.* Diabetic peripheral neuropathy and depressive symptoms: the association revisited. *Diabetes Care* 2005; 28: 2378–2383.

7 Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D *et al.* Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. *Diabetologia* 2009; 52: 1265–1273.

8 Yoshida S, Hirai M, Suzuki S, Awata S, Oka Y. Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes. *Psychiatry Clin Neurosci* 2009; 63: 65–72.

9 Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. *Clin J Pain* 2006; 22: 681–685.

10 American Diabetes Association. Standards of medical care in diabetes—2009. *Diabetes Care* 2009; 32(Suppl 1): S13–S61.

11 Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? *Diabetes Care* 2008; 31(Suppl 2): S255–S261.

12 Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. *BMC Neurol* 2008; 8: 33–45.

13 Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. *Pain* 2005; 115: 254–263.

14 Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. *Neurology* 2004; 63: 2104–2110.

15 Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. *J Pain* 2005; 6: 253–260.

16 Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. *Pain* 2004; 110: 628–638.

17 Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. *Eur J Pain* 2008; 12: 203–213.

18 Ogawa S, Suzuki M, Arakawa A, Araki S, Yoshiyama T. Efficacy and tolerability of pregabalin for postherpetic neuralgia: a multicenter, randomized, double-blind, placebo-controlled clinical trial. *Journal of the Japan Society of Pain Clinicians* 2010; 17: 141–152.

19 van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. *Curr Med Res Opin* 2006; 22: 375–384.

20 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31–41.

21 Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. *J Clin Epidemiol* 1998; 51: 1045–1053.

22 Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *J Jpn Diabetes Soc* 2010; 53: 450–467.

23 Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. *Diabetes Care* 2008; 31: 1448–1454.

24 Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT *et al.* Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain* 2008; 9: 105–121.

25 Quessy SN, Rowbotham MC. Placebo-response in neuropathic pain trials. *Pain* 2008; 138: 479–483.

26 Tavakoli M, Asghar O, Alam U, Petropoulos IN, Fadavi H, Malik RA. Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy. *Ther Adv Endocrinol Metab* 2010; 1: 69–88.

27 Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M *et al.* Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. *Diabetes Care* 2006; 29: 1538–1544.

28 Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. *Biomed Pharmacother* 1995; 49: 269–277.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Appendix S1. List of All Clinical Investigators.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than for missing material) should be directed to the corresponding author for the article.

Research Report

Increased susceptibility to ischemia and macrophage activation in STZ-diabetic rat nerve

Hitoshi Nukada[a,b,*], P. Denise McMorran[a], Masayuki Baba[c], Saori Ogasawara[d], Soroku Yagihashi[d]

[a]Department of Medicine, University of Otago, Dunedin, New Zealand
[b]The Nukada Institute for Medical and Biological Research, Chiba, Japan
[c]Department of Neurology, Aomori Prefecture Medical Center, Aomori, Japan
[d]Department of Pathology and Molecular Medicine, Hirosaki University, Hirosaki, Japan

ARTICLE INFO

ABSTRACT

Ischemic vulnerability in diabetic nerve plays a paramount role in the development of diabetic neuropathy, yet little is known of the underlying mechanism. Diabetes enhances the inflammatory response to ischemia and reperfusion. We investigated pathological characteristics of nerve fibers and endoneurial macrophages along the length of sciatic–tibial nerves before and after ischemia (60 to 90 min) and reperfusion (6 h to 7 days) in 8 weeks of STZ-induced diabetic rats. Without ischemia, diabetic nerves revealed significantly increased the density of Iba-1-positive endoneurial macrophages when compared with controls. Most of macrophages appeared slim and triangular in shape, but in diabetic nerves, some were rounded with bromodeoxyuridine (BrdU) incorporation, suggesting proliferating macrophages. Seventy-five minutes of ischemia is the minimal ischemic time to cause pathological changes in diabetic nerves. Following 90 min of ischemia and 6 h of reperfusion in diabetic rats, the number of Iba-1-positive endoneurial macrophages was increased significantly at the thigh level of sciatic nerve when compared with those before ischemia. Endoneurial macrophages in diabetic nerves increased in number further significantly after 24 and 48 h of reperfusion and underwent morphological alterations; swollen and rounded including phagocytosis. After 90 min of ischemia and 7 days of reperfusion, severe pathological alterations, e.g., demyelination and endoneurial edema at proximal nerves and axonal degeneration distally, were observed in diabetic nerves, while control nerves showed normal morphology. We conclude that macrophage proliferation occurs in STZ-diabetic nerves. The acute inflammatory response after ischemia and reperfusion was intensified in diabetic nerves. Activation of resident macrophages and infiltration by recruited macrophages could be casually linked to ischemic susceptibility in diabetic nerve.

© 2010 Elsevier B.V. All rights reserved.

* Corresponding author. Department of Medicine, University of Otago Medical School, PO Box 913, 201 Great King St, Dunedin, New Zealand 9050. Fax: +64 3 474 7641.
 E-mail address: hitoshi.nukada@otago.ac.nz (H. Nukada).

1.   Introduction

Diabetes enhances ischemic/reperfusion injury in various tissues. We first demonstrated that peripheral nerves in STZ-diabetic rat are susceptible to acute ischemia by either arterial ligation or microsphere embolization (Nukada, 1986, 1992, 1993). A brief or mild ischemia, insufficient to cause nerve fiber damage in normal nerve, results in endoneurial edema, demyelination, axonal degeneration, and necrosis in STZ-diabetic sciatic and tibial nerves. Zochodne and his colleagues demonstrated this property by applying endothelin-1, the most potent vasoconstrictor, in the epineurium of sciatic nerve in STZ-diabetic rats (Zochodne et al., 1996; Zochodne and Cheng, 1999).

We also found aggravated reperfusion injury electrophysiologically and morphologically in STZ-diabetic nerve; delayed recovery of compound muscle action potential, greater endoneurial edema, and prominent axonal degeneration when compared with those in controls (Baba et al., 2006; Nukada et al., 2002). Low and his colleagues confirmed reperfusion exaggerated morphological pathology in STZ-diabetic nerve (Wang et al., 2004). They also showed enhanced inflammatory response nuclear factor-kappa B (NF-κB) activation after reperfusion in STZ-diabetic nerve (Wang et al., 2006). Similar vulnerability to ischemia and reperfusion has been reported in various tissues of diabetes, e.g., brain, heart, and kidney (Anzawa et al., 2006; Di Filippo et al., 2005; Ding et al., 2004; Hearse et al., 1978; Melin et al., 2003; Panagia et al., 2005; Thakker et al., 2008; Yue et al., 2005), and both acute and chronic hyperglycemia aggravate ischemic brain damage (Capes et al., 2001; Gisselsson et al., 1999; Martin et al., 2006; Muranyi et al., 2003; Nedergaard, 1987).

The macrophage has been emerged as an important player in the pathogenesis of both diabetes and diabetic complications. Macrophage accumulation is a feature of diabetes and is associated with development of vascular complications, including both macro- and microangiopathy (Boyle, 2007; Fernandez-Real and Pickup, 2008; Kolb and Mandrup-Poulsen, 2005; Odegaard and Chawla, 2008; Schenk et al., 2008; Tesch, 2007; Toso et al., 2008; Wellen and Hotamisligil, 2005). Macrophages mediate diabetic injury through a variety of mechanisms, including production of reactive oxygen species and cytokines. Reperfusion nerve injury is also a state where oxidative stress has been implicated (Anderson et al., 1997; Frangogiannis et al., 1998; He et al., 1999, 2003; Wang et al., 2005, 2008). Diabetes exaggerates inflammatory responses after ischemia and reperfusion: increased leukocyte–endothelial cell adhesion, albumin extravasation, and oxidant production by endothelial cells in post-capillary venules (Panes et al., 1996; Salas et al., 1998, 1999).

In the current study, we assessed pathological characteristics along the length of sciatic and tibial nerves in STZ-diabetic rats before and after ischemia and reperfusion. We also addressed the hypothesis that macrophage activation and proliferation could be enhanced in reperfused diabetic nerve.

2.   Results

Mean body weights of diabetic and control rats at onset were 231±8 (n=46) and 231±8 (n=46) g, respectively (p>0.05). STZ treatment was associated with a significant attenuation of weight gain at the time of experiment; 343±7 g in diabetic rats and 491±7 g in controls (p<0.0001). STZ-treated rats displayed significant elevation in blood glucose; 29.9±0.5 mmol/l in diabetic rats and 5.5±0.1 mmol/l in controls (p<0.0001). When glucose level was above the scale (>33.3 mmol/l), it was calculated as 33.3 mmol. Motor nerve conduction velocity in sciatic–tibial nerves was reduced in diabetic nerve, being 43.3±0.8 and 53.6±1.0 m/s in diabetic rats and controls respectively (p<0.0001). Results of nerve conduction studies during and after reperfusion in STZ-diabetic rats have been detailed previously (Baba et al., 2006).

2.1.   Nerve pathology

After 8 weeks of STZ-induced diabetes, there was no morphological change in sciatic–tibial nerves. Reperfusion after 60 min of ischemia did not cause any pathological abnormalities in both diabetic and control nerves. However, following 75 min of ischemia and 7 days of reperfusion, diabetic rats revealed focal or multifocal lesions consisting of axonal degeneration, which is the hallmark of an acute ischemic injury (Nukada and Dyck, 1984), at lower thigh and upper calf levels of sciatic and tibial nerves in 4 out of 6 nerves (Fig. 1), whereas nerve morphology was normal in controls.

After 90 min of ischemia and 7 days of reperfusion, diabetic rats exhibited invariably severe pathological abnormalities in sciatic and tibial nerves. At the upper thigh level of sciatic nerve in diabetic rats, the most proximal level evaluated, isolated demyelinated, or thinly myelinated nerve fibers and macrophages with myelin debris were found (Fig. 2A, B). Minimal endoneurial edema was also observed at this level (Fig. 2C, D). At the lower thigh level of diabetic sciatic and tibial nerves, endoneurial edema was more obvious and demyelinated fibers and macrophages were still observed (Fig. 2E, F).

At the upper calf level of tibial nerves after 90 min of ischemia and 7 days of reperfusion in diabetic rats, clusters of demyelinated fibers, macrophages with myelin debris, and severe endoneurial edema with intra-myelinic edema were found (Fig. 3). Demyelinated fibers were often located either near the vessel or macrophages. Control nerves did not reveal demyelinated nerve fibers. Reperfused diabetic nerves also exhibited frequent axonal degeneration (Fig. 3C, D). The density (/mm²) of nerve fibers with axonal degeneration was significantly increased at the upper calf level in diabetic nerve than in controls; 24.0±6.5 and 1.2±2.8, p<0.0001, respectively.

At the lower calf and ankle levels of diabetic tibial nerve, axonal degeneration was prominent. Nerve fibers with axonal degeneration were co-existed with normal myelinated fibers, and focal lesions of axonal degeneration were found though not prominent as at proximal levels (Fig. 4A, B). Diffuse axonal degeneration was also seen in some diabetic rats (Fig. 4C). In contrast, there was normal morphology in control nerves after 90 min of ischemia and 7 day of reperfusion (Fig. 4D). Because of consistent severe pathology, we used 90 min of ischemia for the study of acute inflammatory response after ischemia and reperfusion.

2.2.   Endoneurial macrophages

Immunohistochemical expression of Iba-1 was observed at thigh, knee, and calf levels of sciatic and tibial nerves before

Fig. 1 – Transverse epoxy sections of sciatic and tibial nerves in diabetic rats after 75 min of ischemia and 7 days of reperfusion, showing characteristic pathology in acute ischemic nerve injury. (A) Sciatic nerve at the lower thigh level reveals a focal lesion of axonal degeneration of myelinated nerve fibers at the central fascicular region ("ischemic core"). (B) Tibial nerves at the upper calf level exhibits distinct contrast of myelinated nerve fiber density between a large fascicule on the left and five small fascicules (arrows). Diffuse nerve fiber degeneration is found in small fascicles (arrows), whereas the number of myelinated nerve fibers is preserved in the large fascicle. *Perineurium. Scale bars: 50 μm for both panels.

and after 90 min of ischemia in both diabetic and control nerves. After 8 weeks of STZ-induced diabetes, endoneurial macrophages detected by Iba-1 antibody were distributed throughout the endoneurium. These macrophages appeared slim and triangular and located often close to endothelial cells of endoneurial microvessels in both diabetic and control nerves (Fig. 5A, B). Without an ischemic injury, we found Iba-1-positive macrophages that had incorporated BrdU into their nuclei in diabetic nerves (Fig. 6), but not in controls. These BrdU-positive macrophages in diabetic nerve were swollen and rounded. BrdU did not co-localize with Schwann cell marker S-100, thus providing their identity as proliferating macrophages.

The density (/mm^2) of Iba-1-positive endoneurial macrophages along the length of sciatic and tibial nerves was significantly greater in diabetic rats than in controls: 42.9 ± 2.9 and 34.0 ± 2.6, $p=0.03$ at the thigh level; 44.3 ± 3.5 and 26.7 ± 3.8, $p=0.004$ at the knee level; and 30.8 ± 2.1 and 21.9 ± 1.9, $p=0.008$ at the calf level, in diabetic nerve and controls, respectively. In diabetic nerves, the density of Iba-1-positive endoneurial macrophage was significantly greater at thigh and knee levels than at calf level (thigh vs. calf: $p=0.004$, and knee vs. calf: $p=0.005$). Control nerves also revealed the highest density of Iba-1 macrophages at thigh level of sciatic nerve, although not at significant level statistically. Mean fascicular area of sciatic and tibial nerves was not significantly different between diabetic and control nerves.

After 90 min of ischemia and 6 h of reperfusion in diabetic nerves, the density (/mm^2) of endoneurial Iba-1-positive macrophages increased significantly at thigh level, but not at knee and calf levels, when compared with those before ischemia: 42.9 ± 2.9 and 57.6 ± 2.6, $p=0.001$ at the thigh; 44.3 ± 3.5 and 46.2 ± 2.9, $p=0.68$ at the knee; and 30.8 ± 2.1 and 34.2 ± 2.3, $p=0.29$ at the calf, before ischemia and after 6 h of reperfusion, respectively (Fig. 7). Cell bodies of Iba-1-positive endoneurial macrophages often began to enlarge (Fig. 5C, D). BrdU incorporation was detected in these rounded macrophages, and these changes were more promi-

nent after 24 h of reperfusion. Nerve fiber morphology was normal, and the mean fascicular area at each level was not significantly different from pre-ischemia.

After 90 min of ischemia and 24 h of reperfusion in diabetic nerves, the density (/mm^2) of Iba-1-positive endoneurial macrophages was significantly increased further at thigh and knee levels, but not at the calf level, when compared with those after 6 h of ischemia: 57.6 ± 2.6 and 71.5 ± 2.7, $p=0.002$ at the thigh; 46.2 ± 2.9, and 58.2 ± 3.2, $p=0.01$ at the knee; and 34.2 ± 2.3 and 36.8 ± 3.2, $p=0.52$ at the calf, after 6 h and 24 h of reperfusion, respectively (Fig. 7). Morphologically, there were empty axons, endoneurial edema and intra-myelinic edema at lower thigh and upper calf levels of diabetic nerves. These pathological features were more prominent after 48 h of reperfusion.

After 90 min of ischemia and 48 h of reperfusion, most macrophages were rounded and appeared like phagocytic cells in diabetic nerves (Fig. 5E). Some of these macrophages at thigh and kneel levels in diabetic nerves showed phagocytosis of myelin debris and lipid droplets (Fig. 5F). After 48 h of reperfusion, the density (/mm^2) of Iba-1 endoneurial-positive cells further increased significantly at all levels along the length of sciatic–tibial nerves when compared with those after 24 h of reperfusion: 71.5 ± 2.7 and 109.0 ± 3.4, $p<0.0001$ at the thigh; 58.2 ± 3.2, and 149.9 ± 10.1, $p<0.0001$ at the knee; and 36.8 ± 3.2 and 103.7 ± 8.7, $p<0.0001$ at the calf, after 24 h and 48 h of reperfusion, respectively (Fig. 7). In sciatic and tibial nerves from control rats, Iba-1-positive endoneurial macrophages increased, although not at significant level statistically; p values >0.05 at all levels and all time points (Fig. 7). After 90 min of ischemia and 72 h or later of reperfusion in diabetic nerves, the number of Iba-1-positive macrophages increased continuously and the most of macrophages showed phagocytosis. Following 7 days of reperfusion in diabetic nerves, ED1- and ED2-positive endoneurial macrophages with phagocytosis were also seen in diabetic nerves.

Fig. 2 – Nerve pathology after 90 min of ischemia and 7 days of reperfusion at the upper thigh (A–D) and lower thigh (E, F) levels of sciatic and tibial nerves from diabetic rats. (A) Macrophage with myelin debris (arrow) was surrounded by normal myelinated nerve fibers. (B) Demyelinated nerve fiber was located near the endoneurial vessel (arrowhead). Intra-myelinic edema was also observed (arrow). (C, D) Myelinated nerve fiber with disproportionately thin myelin and extensive cytoplasm around axon (arrow) suggests macrophages invading Schwann cells, although it is often difficult to distinguish Schwann cells containing myelin debris from macrophages by light microscopy. (E) At the lower thigh level of tibial nerve, demyelination (arrow) and endoneurial edema were seen. (F) Demyelinated nerve fiber with naked axon shown in E was confirmed by electron micrograph. Scale bars: 10 μm (A–E); 2 μm (F).

3.   Discussion

This study confirmed that the ischemic threshold to cause abnormal nerve morphology in diabetic nerves is 75 min. Seventy-five minutes of ischemia could result in axonal degeneration in STZ-diabetic nerve. After 90 min of ischemia, severe nerve pathology was consistently observed along the length of sciatic and tibial nerves in diabetic rats, e.g.,

demyelination, activated macrophages, endoneurial edema at thigh and knee levels, and axonal degeneration distally. In control nerves, 4–5 h of severe ischemia needs to induce similar morphological changes (Gray et al., 2003; Nukada and McMorran, 1994; Nukada et al., 1997). In our previous studies of reperfusion nerve injury, we demonstrated demyelinated fibers particularly at perivascular region, endoneurial edema, intra-myelinic edema, and axonal degeneration at proximal nerve segments and panfascicular necrosis at distal levels after 5 h of ischemia

Fig. 3 – Nerve pathology after 90 min of ischemia and 7 days of reperfusion at the upper calf level of tibial nerve from diabetic rats showing demyelination, endoneurial edema, and axonal degeneration. (A) Demyelinated nerve fiber (arrow) was accompanied by a macrophage with myelin debris. (B) High magnification of a demyelinated fiber and a macrophage shown in A. (C) A cluster of nerves fibers with demyelination (arrows) and axonal degeneration were observed. It is often hard to distinguish naked axons from axons with one or two layers of myelin by light microscope. (D) Nerve fibers with demyelination (arrows) and axonal degeneration were observed with severe endoneurial edema and intra-myelinic edema. (E, F) Electron micrographs of demyelinated nerve fibers and endoneurial edema from the nerve shown in A and B. Note a monocyte beside a demyelinated fiber. Scale bars: 10 μm (A–D); 5 μm (E, F).

and 7 days of reperfusion in non-diabetic rats (Nukada and McMorran, 1994; Nukada et al., 1997). These pathological changes at thigh and knee levels are caused by reperfusion, while morphological changes at ankle level are induced by no-reflow phenomenon (Nukada et al., 1997). In the current study, we showed similar pathological changes in diabetic nerves after

90 min of ischemia, although the duration of ischemia is not long enough to cause no-reflow phenomenon at distal levels.

After 8 weeks of STZ-induced diabetes, the density of Iba-1-positive endoneurial macrophages increased significantly in sciatic and tibial nerves when compared with those in control nerves. Most of these endoneurial macrophages were slim and

Fig. 4 – Nerve pathology after 90 min of ischemia and 7 days of reperfusion at the lower calf/ankle level of tibial nerve from diabetic (A–C) and control (D) rats. Axonal degeneration was prominent at this level in diabetic nerves. (A, B) Nerve fibers with axonal degeneration were scattered among normal myelinated fibers, although there are multifocal lesions to a certain degree. Approximately a half of myelinated nerve fibers shows axonal degeneration. (C) Myelinated nerve fibers exhibit various stages of axonal degeneration. Note accumulation and adhesion of circulating white blood cells in the endoneurial venule. (D) Control nerve reveals normal nerve morphology. *Perineurium. Scale bars: 50 μm (A, B), 20 μm (C, D).

triangular in shape, but some of them were rounded and colabelled with BrdU. It is also noted that endoneurial macrophages were not distributed evenly along the length of sciatic and tibial nerves. In diabetic rats, the density of endoneurial macrophages was significantly greater at thigh and knee levels than at calf level. A similar trend was seen in control nerves, although not significant statistically. These data indicate that hyperglycemia, per se, results in macrophage proliferation at thigh and knee levels of the diabetic nerve. Macrophage proliferation may occur at this level because of anatomic watershed zone of poor perfusion (Dyck et al., 1972; Dyck, 1989; Nukada and Dyck, 1984). A substantial increase in tissue macrophages is a common feature of type 2 diabetic vascular complications, including atherosclerosis, retinopathy, and nephropathy (Ehses et al., 2008; Tesch, 2007; Wellen and Hotamisligil, 2005). Various metabolic abnormalities secondary to hyperglycemia promote macrophage accumulation and activation within diabetic tissue. Subsequently macrophages mediate diabetic injury through a variety of mechanisms, i.e., expressing a plethora of regulatory cytokines and secreting free radicals. In STZ-diabetic nerve, an increased number of ED-1-positive endoneurial macrophages were inhibited significantly by pioglitazone, peroxisome proliferator-activated receptor γ (PPARγ)-ligand, treatment for 12 weeks (Yamagishi et al., 2008).

After 90 min of ischemia and 6, 24, and 48 h of reperfusion, the density of Iba-1 endoneurial macrophages increased significantly in diabetic nerves, but not in control nerves. Following 6 h of reperfusion, the number of endoneurial macrophages increased significantly at the thigh level, but not at knee and calf levels, of diabetic sciatic nerve when compared with those before ischemia. Subsequently, macrophage proliferation extended distally along the length of sciatic and tibial nerves in diabetic rats. After 24 h of reperfusion, the density of macrophages increased significantly at thigh and knee levels, when compared with those at 6 h. Following 48 h of reperfusion, the density of endoneurial macrophages increased significantly, in further, to 2.5-fold at thigh and 3.4-fold at knee and calf levels compared with pre-ischemic level in diabetic nerves. In our previous study, a similar trend of increased number of endoneurial macrophage was found in non-diabetic nerve after a longer period of ischemia. After 5 h of ischemia and 48 h of reperfusion, IC-7-positive endoneurial macrophages increased nearly 4-fold, and macrophage-associated inflammatory demyelination was observed after reperfusion (Nukada et al., 2000). Because the most severe ischemia was achieved at mid- and lower-thigh, and knee levels in the current model of an ischemic injury (Dyck et al., 1984; Nukada and Dyck, 1984; Nukada and McMorran, 1994; Nukada et al., 1997), macrophage proliferation was originally generated by reperfusion

Fig. 5 – Endoneurial macrophages identified by the polyclonal macrophage antibody against Iba-1 in diabetic nerve before (A, B) and after 90 min of ischemia and 6 h (C, D) and 48 h (E, F) of reperfusion at the thigh level of sciatic and tibial nerves. (A, B) Before ischemia, endoneurial macrophages are small or skinny with a triangular or longitudinal shape. They are often positioned around endoneurial vessels. (C, D) After 90 min of ischemia and 6 h of reperfusion, the number of Iba-1-positive endoneurial macrophages increased, and cell bodies of many Iba-1-positive macrophages were enlarged or rounded. (E, F) After 90 min of ischemia and 48 h of reperfusion, Iba-1-positive endoneurial macrophages reveal phagocytosis with lipid debris. Blue nuclear counterstain with hematoxylin. v: Endoneurial vessel. *Perineurium. Scale bars: 10 μm for all panels.

injury at the thigh level of sciatic nerve and reached at distal levels 48 h later.

Endoneurial macrophages are crucially involved in the pathogenesis of peripheral neuropathies. In addition to infiltrating hematogenous macrophages, a population of local resident macrophages has long been recognized in the peripheral nerve (Griffin and George, 1993; Griffin et al., 1993). In the current study, it is impossible to distinguish resident endoneurial macrophages from infiltrating haematogenous macrophages. Muller and his

colleagues have demonstrated elegantly a crucial role of resident endoneurial macrophages using bone marrow chimeric mice carrying green fluorescent protein (GFP) transgenic bone marrow, allowing the differentiation of resident (GFP⁻) and invading hematogenous (GFP⁺) macrophages (Mueller et al., 2001, 2003). They reported that the peripheral nervous system is able to generate an intrinsic macrophages reaction by resident macrophages (Muller et al., 2008). Only in the case of more severe nerve damage, an additional influx of hematogenous macrophages is

Fig. 6 – After 8 weeks of diabetes without an ischemic injury BrdU incorporation was detected among Iba-1-positive endoneurial macrophages at the thigh level of sciatic nerve, suggesting proliferating macrophages (arrows). Note these BrdU-colabelled macrophages were rounded. Scale bar: 20 μm.

initiated. Proliferating resident macrophages were peaked 3 days after crush injury in sciatic nerve, and the influx of hematogenous macrophages begins around day 4 (Mueller et al., 2001). Myelin phagocytosis by resident macrophages was demonstrated as early as 2 days after injury and was found to be one of the first features of endoneurial macrophage activation. These collective data support the notion that the resident macrophages may orchestrate the inflammatory response that occurs in the acute phase of reperfusion nerve injury. Iba-1-positive macrophages after 6 to 48 h of reperfusion injury in diabetic rats may be much earlier than post-traumatic infiltration of hematogenous macrophages.

Intracellular oxidative stress has been proposed as a unifying explanation for the development of diabetic vascular complications (Cameron and Cotter, 2008; Jay et al., 2006; Pacher and Szabo, 2006; Pop-Busui et al., 2006; Zochodne, 2007) and of reperfusion injury (Frangogiannis et al., 1998) including reperfusion nerve injury (Anderson et al., 1997; He et al., 1999, 2003; Wang et al., 2005). It could be speculated that the oxidative stress from hyperglycemia and reperfusion injury could be particularly harmful. The exaggerated inflammatory response after ischemia and reperfusion shown in the current study may result in morphological susceptibility to ischemia and reperfusion in diabetic nerves, although the role of the enhanced inflammatory response needs to be clarified. Diabetic subjects may suffer from severe neuropathic damage even after normally tolerable ischemia and reperfusion. Pathways controlling macrophage activation can potentially be targeted to improve recovery from ischemic nerve injury in diabetic subjects.

4. Experimental procedures

4.1. Animals

Male Wistar rats (7–8 weeks old) were purchased from CLEA Japan Inc., Tokyo, Japan. Rats were fasted overnight prior to i.v. injection of either 40 mg/kg STZ (Sigma, St Louis, MO, USA) in


Fig. 7 – Quantification of Iba-1-positive endoneurial macrophage before and after 90 min of ischemia and 6, 24, and 48 h of reperfusion at thigh, knee, and calf levels of sciatic and tibial nerves from diabetic (A) and control (B) rats. (A) After 6 h of reperfusion, the density of Iba-1-positive endoneurial macrophages in diabetic nerves increased significantly at thigh level, but not at knee and ankle levels, when compared with pre-ischemia level. The density of macrophages in diabetic nerves increased significantly at thigh and knee levels after 24 h of reperfusion and at all three levels after 48 h when compared with 6 h and 24 h, respectively. (B) The density of Iba-1-positive endoneurial macrophages in control nerves did not significantly differ before and after ischemia and reperfusion. Statistically significant differences denoted by $p < 0.05$, $p < 0.01$, $p < 0.0001$. ANOVA: in diabetic nerves, proximal; $p < 0.0001$, mid; $p = 0.0002$, distal; $p = 0.001$, and in controls, proximal; $p = 0.16$, mid; $p = 0.40$, distal; $p = 0.45$.

0.1 mol/l citrate buffer or buffer alone. Following injection, rats were returned to their cages, maintained under standard 12-h light–dark cycle, and given free access to food and water for the remainder of the study. Rats were considered diabetic if non-fasting blood glucose concentration was >19.4 mmol/l (350 mg/dl) at 7 days after the STZ injection and the time of experiment. All animal protocols in this study were approved by the Committee on Ethics in the Care and Use of Laboratory Animals, University of Otago, and the Committee for Animal Experimentation, Hirosaki University, and conform to National Institute of Health guidelines stated in "Principles of laboratory animal care" (NIH publication no. 85-23, revised 1985).

4.2. Ischemia and reperfusion injury

The surgery to produce an ischemic/reperfusion injury was performed 8 weeks after the STZ injection. The methods for inducing ischemia/reperfusion have been detailed previously (Nukada and McMorran, 1994). In brief, rats were anesthetized with pentobarbital (0.4 mg/100 g BW i.p.) and were placed on a heating pad. Major arteries supplying the right hindlimb, abdominal aorta, right common iliac artery, right femoral, and right superficial circumflex iliac arteries were occluded by microvascular clips (TSK-1 40 g, Kyowa, Tokyo, Japan). Reperfusion was achieved by release of these vascular clips. Control group received sham surgery only. The right hindlimb temperature was kept 35±1 °C during surgical procedures. Duration of ischemia was 60, 75, and 90 min. The duration of ischemia has been determined from our previous studies (Baba et al., 2006; Nukada and McMorran, 1994; Nukada et al., 1997, 2002).

4.3. Morphological evaluation

The morphology of sciatic and tibial nerves in right hindlimb were evaluated (1) without an ischemic injury in diabetic (n=8) and control (n=8) rats; (2) after 90 min of ischemia and 6, 24, 48, and 72 h and 7 days of reperfusion; and (3) after 60, and 75 min of ischemia and 7 days of reperfusion in diabetic (n=12) and control (n=12) rats. The group of 90-min ischemia consisted of 32 rats each from diabetic and control group. Bromodeoxyuridine (BrdU, 50 mg/kg BW i.p.) was injected 60 min before nerves were taken. Nerves were processed using previously described methods (Nukada and Dyck, 1984). Right sciatic and tibial nerves were dissected in continuity from the pelvic level to the ankle. The entire length of nerve was taken in continuity and cut into consecutive segments: pelvic to upper thigh (approx. 5 mm), mid-thigh (10 mm), lower-thigh (5 mm), knee (10 mm), upper calf (5 mm), calf (10 mm), and lower calf/ankle (5 mm) levels. Each 10-mm nerve segment at thigh, knee, and calf levels was processed for paraffin blocks of immunohistochemical examination. Adjacent 5-mm segments were fixed for epon-embedded blocks. Nerves for epon blocks were fixed with 2.5% glutaraldehyde in 0.025 M cacodylate buffer, pH 7.40, overnight, and then postfixed in 1% osmium tetroxide, dehydrated, and cut into consecutive 2- to 3-mm blocks before embedding in epoxy resin. Semi-thin sections (1-μm in thickness) were stained with methylene blue.

4.4. Immunohistochemistry

Immunohistochemical studies were performed before and after 90 min of ischemia. Nerve segments for immunohistochemical evaluation were fixed in 10% buffered neutral formalin. Sections were stained using the avin–biotin–peroxidase complex method (Histofine, Nitirei, Tokyo, Japan) as previously described (Nukada et al., 2000). After deparaffinization, the specimens were microwaved in 0.01 M citrate buffer, pH 6.0, for three 5-min periods. Endogenous peroxidase was blocked by 3% H$_2$O$_2$ followed by washing in PBS. Sections were then incubated for 15 min with 10% normal goat serum in PBS to block non-specific staining and incubated the primary antibody overnight 4 °C. Subsequently, incubation with the

secondary antibody was performed for 30 min. The detection of the reaction was carried out with 3′3′diaminobenzidine tetrahydrochloride (DAB, 0.5 mg/ml, Sigma, USA). Concurrent controls included replica sections in which bridging antibody substituted for nonbinding control antibody, and positive control sections from rat spleen, liver, and thymus. The following anti-rat antibodies were used: Iba-1 (ionized calcium-binding adaptor molecule 1, Wako), ED1 and ED2 (Serotec) that recognize macrophages, and S100 (Abcam, Cambridge, UK) reacts with Schwann cells. Mouse anti-rat BrdU was colabelled to identify cellular activity.

Double labelling was performed in two steps: (1) first antigen retrieval 5 min in citrate buffer in microwave over three times, followed by overnight incubation with primary antibody. The reaction was developed with alkaline phosphates using New Fucsin (Nichirei, Tokyo, Japan) as a chromogan; (2) overnight incubation with BrdU and development with peroxidase and DAB as a chromogen. Three types of negative controls were designed: rats without BrdU administration, nonbinding primary antibody, and the positive control.

4.5. Morphometry

For morphometric analysis, the entire transverse fascicles were examined for the localization of immunoreactive cells. The total fascicular area of transverse sections was determined using a NIH image analysis, and the number of positively stained endoneurial cells was counted manually in a blinded fashion. The density of these positive cells (/mm^2) was calculated at thigh, knee, and calf levels of sciatic and tibial nerves.

4.6. Nerve conduction study

Nerve conduction study in sciatic–tibial nerves was made before ischemia as previously described (Baba et al., 2006). Motor conduction velocity and compound muscle action potential (CMAP) were measured using needle near-nerve stimulating and recording electrodes. The CMAP was recorded from the dorsum of the hind paw while simulating at the level of the sciatic notch. The right hindlimb temperature was kept 35±1 °C using a heating pad.

4.7. Statistics

Data are presented as means±SEM. Statistical differences between groups were analyzed by unpaired Student's t-test and one-way ANOVA as appropriate (GraphPad InStat, San Diego, CA). Data that did not follow normal Gaussian distribution were analyzed by a nonparametric Mann–Whitney test. Values of $p < 0.05$ were considered statistically significant.

REFERENCES

Anderson, G.M., Nukada, H., McMorran, P.D., 1997. Carbonyl histochemistry in rat reperfusion nerve injury. Brain Res. 772, 156–160.

Anzawa, R., Bernard, M., Tamareille, S., Baetz, D., Confort-Gouny, S., Gascard, J.P., Cozzone, P., Feuvray, D., 2006. Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice. Diabetologia 49, 598–606.

Baba, M., Nukada, H., McMorran, D., Takahashi, K., Wada, R., Yagihashi, S., 2006. Prolonged ischemic conduction failure after reperfusion in diabetic nerve. Muscle Nerve 33, 350–355.

Boyle, P.J., 2007. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120, S12–S17.

Cameron, N.E., Cotter, M.A., 2008. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr. Drug Targets 9, 60–67.

Capes, S.E., Hunt, D., Malmberg, K., Pathak, P., Gerstein, H.C., 2001. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32, 2426–2432.

Di Filippo, C., Marfella, R., Cuzzocrea, S., Piegari, E., Petronella, P., Giugliano, D., Rossi, F., D'Amico, M., 2005. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 54, 803–810.

Ding, C., He, Q., Li, P.A., 2004. Activation of cell death pathway after a brief period of global ischemia in diabetic and non-diabetic animals. Exp. Neurol. 188, 421–429.

Dyck, P.J., Conn, D.L., Okazaki, H., 1972. Necrotizing angiopathic neuropathy. Three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin. Proc. 47, 461–475.

Dyck, P.J., Karnes, J., O'Brien, P., Nukada, H., Lais, A., Low, P., 1984. Spatial pattern of nerve fiber abnormality indicative of pathologic mechanism. Am. J. Pathol. 117, 225–238.

Dyck, P.J., 1989. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture. Neurology 39, 111–118.

Ehses, J.A., Boni-Schnetzler, M., Faulenbach, M., Donath, M.Y., 2008. Macrophages, cytokines and beta-cell death in Type 2 diabetes. Biochem. Soc. Trans. 36, 340–342.

Fernandez-Real, J.M., Pickup, J.C., 2008. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 19, 10–16.

Frangogiannis, N.G., Youker, K.A., Rossen, R.D., Gwechenberger, M., Lindsey, M.H., Mendoza, L.H., Michael, L.H., Ballantyne, C.M., Smith, C.W., Entman, M.L., 1998. Cytokines and the microcirculation in ischemia and reperfusion. J. Mol. Cell. Cardiol. 30, 2567–2576.

Gisselsson, L., Smith, M.L., Siesjo, B.K., 1999. Hyperglycemia and focal brain ischemia. J. Cereb. Blood Flow Metab. 19, 288–297.

Gray, C., Nukada, H., Jackson, D.M., McMorran, P.D., Wu, A., Ma, F., 2003. Neuroprotective effects of nitrone radical scavenger S-PBN on reperfusion nerve injury in rats. Brain Res. 982, 179–185.

Griffin, J.W., George, R., 1993. The resident macrophages in the peripheral nervous system are renewed from the bone marrow: new variations on an old theme. Lab Invest. 69, 257–260.

Griffin, J.W., George, R., Ho, T., 1993. Macrophage systems in peripheral nerves. A review. J. Neuropathol. Exp. Neurol. 52, 553–560.

He, K., Nukada, H., McMorran, P.D., Murphy, M.P., 1999. Protein carbonyl formation and tyrosine nitration as markers of oxidative damage during ischaemia-reperfusion injury to rat sciatic nerve. Neuroscience 94, 909–916.

He, K., Nukada, H., Urakami, T., Murphy, M.P., 2003. Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ):

implications for its function in biological systems. Biochem. Pharmacol. 65, 67–74.

Hearse, D.J., Stewart, D.A., Green, D.G., 1978. Myocardial susceptibility to ischemic damage: a comparative study of disease models in the rat. Eur. J. Cardiol. 7, 437–450.

Jay, D., Hitomi, H., Griendling, K.K., 2006. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 40, 183–192.

Kolb, H., Mandrup-Poulsen, T., 2005. An immune origin of type 2 diabetes? Diabetologia 48, 1038–1050.

Martin, A., Rojas, S., Chamorro, A., Falcon, C., Bargallo, N., Planas, A. M., 2006. Why does acute hyperglycemia worsen the outcome of transient focal cerebral ischemia? Role of corticosteroids, inflammation, and protein O-glycosylation. Stroke 37, 1288–1295.

Melin, J., Hellberg, O., Fellstrom, B., 2003. Hyperglycaemia and renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant. 18, 460–462.

Mueller, M., Wacker, K., Ringelstein, E.B., Hickey, W.F., Imai, Y., Kiefer, R., 2001. Rapid response of identified resident endoneurial macrophages to nerve injury. Am. J. Pathol. 159, 2187–2197.

Mueller, M., Leonhard, C., Wacker, K., Ringelstein, E.B., Okabe, M., Hickey, W.F., Kiefer, R., 2003. Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages. Lab Invest. 83, 175–185.

Muller, M., Wacker, K., Getts, D., Ringelstein, E.B., Kiefer, R., 2008. Further evidence for a crucial role of resident endoneurial macrophages in peripheral nerve disorders: lessons from acrylamide-induced neuropathy. Glia 56, 1005–1016.

Muranyi, M., Fujioka, M., He, Q., Han, A., Yong, G., Csiszar, K., Li, P.A., 2003. Diabetes activates cell death pathway after transient focal cerebral ischemia. Diabetes 52, 481–486.

Nedergaard, M., 1987. Transient focal ischemia in hyperglycemic rats is associated with increased cerebral infarction. Brain Res. 408, 79–85.

Nukada, H., Dyck, P.J., 1984. Microsphere embolization of nerve capillaries and fiber degeneration. Am. J. Pathol. 115, 275–287.

Nukada, H., 1986. Increased susceptibility to ischemic damage in streptozocin-diabetic nerve. Diabetes 35, 1058–1061.

Nukada, H., 1992. Mild ischemia causes severe pathological changes in experimental diabetic nerve. Muscle Nerve 15, 1116–1122.

Nukada, H., 1993. The susceptibility of rat diabetic nerve to ischemia: increased or decreased? J. Neurol. Sci. 119, 162–168.

Nukada, H., McMorran, P.D., 1994. Perivascular demyelination and intramyelinic oedema in reperfusion nerve injury. J. Anat. 185 (Pt 2), 259–266.

Nukada, H., Anderson, G.M., McMorran, P.D., 1997. Reperfusion nerve injury: pathology due to reflow and prolonged ischaemia. J. Peripher. Nerv. Syst. 2, 60–69.

Nukada, H., McMorran, P.D., Shimizu, J., 2000. Acute inflammatory demyelination in reperfusion nerve injury. Ann. Neurol. 47, 71–79.

Nukada, H., Lynch, C.D., McMorran, P.D., 2002. Aggravated reperfusion injury in STZ-diabetic nerve. J. Peripher. Nerv. Syst. 7, 37–43.

Odegaard, J.I., Chawla, A., 2008. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat. Clin. Pract. Endocrinol. Metab. 4, 619–626.

Pacher, P., Szabo, C., 2006. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr. Opin. Pharmacol. 6, 136–141.

Panagia, M., Gibbons, G.F., Radda, G.K., Clarke, K., 2005. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am. J. Physiol. Heart Circ. Physiol. 288, H2677–H2683.

Panes, J., Kurose, I., Rodriguez-Vaca, D., Anderson, D.C., Miyasaka, M., Tso, P., Granger, D.N., 1996. Diabetes exacerbates

inflammatory responses to ischemia–reperfusion. Circulation 93, 161–167.

Pop-Busui, R., Sima, A., Stevens, M., 2006. Diabetic neuropathy and oxidative stress. Diab. Metab Res Rev. 22, 257–273.

Salas, A., Panes, J., Elizalde, J.I., Casadevall, M., Anderson, D.C., Granger, D.N., Pique, J.M., 1998. Mechanisms responsible for enhanced inflammatory response to ischemia–reperfusion in diabetes. Am. J. Physiol. 275, H1773–H1781.

Salas, A., Panes, J., Elizalde, J.I., Granger, D.N., Pique, J.M., 1999. Reperfusion-induced oxidative stress in diabetes: cellular and enzymatic sources. J. Leukoc. Biol. 66, 59–66.

Schenk, S., Saberi, M., Olefsky, J.M., 2008. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118, 2992–3002.

Tesch, G.H., 2007. Role of macrophages in complications of type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 34, 1016–1019.

Thakker, G.D., Frangogiannis, N.G., Zymek, P.T., Sharma, S., Raya, J.L., Barger, P.M., Taegtmeyer, H., Entman, M.L., Ballantyne, C.M., 2008. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obes. Silver Spring. 16, 2593–2600.

Toso, C., Emamaullee, J.A., Merani, S., Shapiro, A.M., 2008. The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. Diabetologia 51, 1937–1946.

Wang, Y., Schmelzer, J.D., Schmeichel, A., Iida, H., Low, P.A., 2004. Ischemia–reperfusion injury of peripheral nerve in experimental diabetic neuropathy. J. Neurol. Sci. 227, 101–107.

Wang, Y., Schmeichel, A.M., Iida, H., Schmelzer, J.D., Low, P.A., 2005. Ischemia–reperfusion injury causes oxidative stress and apoptosis of Schwann cell in acute and chronic experimental diabetic neuropathy. Antioxid. Redox Signal. 7, 1513–1520.

Wang, Y., Schmeichel, A.M., Iida, H., Schmelzer, J.D., Low, P.A., 2006. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury. J. Neurol. Sci. 247, 47–52.

Wang, Y., Kawamura, N., Schmelzer, J.D., Schmeichel, A.M., Low, P.A., 2008. Decreased peripheral nerve damage after ischemia-reperfusion injury in mice lacking TNF-alpha. J. Neurol. Sci. 267, 107–111.

Wellen, K.E., Hotamisligil, G.S., 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111–1119.

Yamagishi, S., Ogasawara, S., Mizukami, H., Yajima, N., Wada, R., Sugawara, A., Yagihashi, S., 2008. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats. J. Neurochem. 104, 491–499.

Yue, T.L., Bao, W., Gu, J.L., Cui, J., Tao, L., Ma, X.L., Ohlstein, E.H., Jucker, B.M., 2005. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54, 554–562.

Zochodne, D.W., Cheng, C., Sun, H., 1996. Diabetes increases sciatic nerve susceptibility to endothelin-induced ischemia. Diabetes 45, 627–632.

Zochodne, D.W., Cheng, C., 1999. Diabetic peripheral nerves are susceptible to multifocal ischemic damage from endothelin. Brain Res. 838, 11–17.

Zochodne, D.W., 2007. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 36, 144–166.

Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan

Hitoshi Yasuda[1]*, Nigishi Hotta[2], Kazuwa Nakao[3], Masato Kasuga[4], Atsunori Kashiwagi[5], Ryuzo Kawamori[6]

ABSTRACT

Aims/Introduction: Duloxetine has been suggested to exert analgesic effects by activating the descending inhibitory system through inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake. This randomized controlled trial investigated the efficacy and safety of duloxetine in Japanese patients with diabetic neuropathic pain (DNP).
Materials and Methods: Duloxetine 40 or 60 mg/day or placebo was given orally once daily for 12 weeks. The primary efficacy measure was weekly mean 24-h average pain severity score on the 11-point Numerical Rating Scale.
Results: At 12 weeks vs baseline, the 24-h average pain score (adjusted mean ± SE) was significantly improved in the combined duloxetine (−2.47 ± 0.18) and duloxetine 40 mg (−2.41 ± 0.21) and 60 mg groups (−2.53 ± 0.21) as compared with the placebo group (−1.61 ± 0.18). Duloxetine also exerted significant improvements over the placebo in nearly all secondary outcome measures including 24-h worst pain, night pain, Brief Pain Inventory (BPI) pain scores, Patient's Global Impression of Improvement (PGI-I) and health outcome measures, namely, various BPI interference scores. The incidence of adverse events (AE) was higher in the duloxetine groups than in the placebo group (duloxetine overall, 84.8%; duloxetine 40 mg, 84.7%; duloxetine 60 mg, 84.9%; placebo, 73.7%). Most AE were mild or moderate in severity, and resolved or relieved. There were no clinically significant safety concerns.
Conclusions: Duloxetine 40 or 60 mg/day showed superiority over the placebo at reducing pain scores in patients with DNP. Duloxetine is safe, efficacious and clinically useful in the management of DNP. This trial was registered with ClinicalTrials.gov (no. NCT-00552175). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00073.x, 2011)

KEY WORDS: Diabetic neuropathic pain, Duloxetine, Serotonin and noradrenaline reuptake inhibitor

INTRODUCTION

Recently, the number of diabetic patients in Japan has increased. It is now thought to amount to 8.9 million, or 22.1 million when including incipient diabetic individuals[1]. Among three major complications of diabetes mellitus, diabetic neuropathy seems to have the highest incidence, with 36.7% of diabetic patients reported to be suffering from this condition[2].

Diabetic neuropathic pain (DNP) is characterized by the symptomatic nature of an aching, burning, tingling or stabbing sensation[3]. DNP not only is often increased at night and affects sleep[4], but also interferes with daily life, leading to deterioration of quality of life and a depressive state in severe cases[5].

Epalrestat and mexiletine hydrochloride are approved and widely used in Japan for the indication of DNP. Drugs listed as therapeutic options for DNP in *Evidence-based Practice Guideline for the Treatment of Diabetes in Japan*[6] include epalrestat, mexiletine hydrochloride, antidepressants, anticonvulsants, nonsteroidal anti-inflammatory drugs (NSAIDs) and sustained-release oxycodone. NSAIDs might be efficacious against mild DNP, but not against moderate and severe forms. Tricyclic antidepressants, certain anticonvulsants and opioid analgesics are recommended for the treatment DNP, but might be limited by side effects[7].

Serotonin (5-HT) and noradrenaline (NA) have been implicated in the modulation of intrinsic analgesic mechanisms through descending inhibitory neurons in the brain and spinal cord[8–11]. An imbalance in these neurotransmitter mechanisms might contribute to central sensitization and hyperexcitability, thereby leading to persistent pain in DNP[12]. Current evidence suggests that antidepressants that have been shown to have analgesic effects in pain conditions exert such analgesic effects independent of improvement in mood or anxiety[13,14]. Instead, potentiation of 5-HT and NA activity in the central nervous system (CNS) through inhibition of their reuptake has been suggested as a probable mechanism of the analgesic action of antidepressants against neuropathic pain[15,16].

[1]Department of Community Life Nursing, Shiga University of Medical Science, Shiga, [2]Chubu Rosai Hospital, Nagoya, [3]Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, [4]Research Institute, National Center for Global Health and Medicine, Tokyo, [5]Shiga University of Medical Science Hospital, Shiga, and [6]Department of Medicine, Metabolism & Endocrinology, Juntendo University School of Medicine, Tokyo, Japan
*Corresponding author. Hitoshi Yasuda Tel.: +81-77-548-2399 Fax: +81-77-543-2399
E-mail address: hyasuda@belle.shiga-med.ac.jp